Physiological Role and Mechanism of Action
In the coagulation cascade, thrombin (activated factor IIa) is the key enzyme. It is generated from its inactive precursor, prothrombin (factor II).
Prothrombin activation is driven by the prothrombinase complex, which consists of three components:
- activated factor Xa;
- cofactor factor Va;
- calcium ions ($Ca^{2+}$).
This complex cleaves prothrombin into active thrombin. In the final stage of coagulation, thrombin catalyzes the partial proteolysis of fibrinogen, producing fibrin, whose strands form the structural framework of any thrombus.
Formulation and Clinical Application
In clinical practice, Thrombinum is used exclusively as a topical hemostatic agent.
- Formulation: Ampoules and vials containing at least 125 IU of activity.
- Administration: The contents of the vial must be dissolved in 2–50 mL of sterile 0.9% sodium chloride ($NaCl$) solution. The resulting solution is sprayed or irrigated onto the bleeding surface to rapidly stop hemorrhage.
Pharmacological Regulation: Thrombin Inhibitors
Because thrombin is the central enzyme in coagulation, it is a primary target for anticoagulants. Its activity can be suppressed via two main pathways: indirectly (via a cofactor) or by direct binding.
1. Antithrombin III-Dependent Anticoagulants
Endogenous antithrombin III inactivates thrombin (as well as factors Xa, IXa, XIa, and XIIa). In the presence of heparin or heparan sulfate (found on the surface of undamaged endothelium), this inactivation rate increases 1000-fold. Agents in this group affect thrombin differently:
- Unfractionated heparin (UFX): Non-selective, inhibiting thrombin (IIa) and factor Xa equally (1:1 ratio).
- Low-molecular-weight heparins (LMWHs): (e.g., enoxaparin, nadroparin) preferentially inhibit factor Xa, with significantly weaker activity against thrombin (2:1 to 4:1 ratio).
- Clinical note: Prolonged heparin administration depletes endogenous antithrombin III reserves, reducing the efficacy of thrombin inhibition and necessitating antithrombin III replacement therapy.
Structural features: A unique pentasaccharide sequence is required to activate antithrombin III. Only about 30% of standard heparin molecules contain this sequence. The synthetic drug fondaparinux sodium consists solely of this pentasaccharide; however, it is highly selective and inhibits factor Xa exclusively, with no effect on thrombin.
2. Direct Thrombin Inhibitors
These anticoagulants bind directly to the thrombin molecule without requiring antithrombin III. They are classified by their binding sites on the enzyme:
- Bivalent inhibitors (dual-site blockers): Bind simultaneously to the catalytic center (responsible for proteolysis) and the substrate-recognition site (anion-binding exosite 1). Examples include hirudin, lepirudin, and bivalirudin.
- Univalent inhibitors (active-site blockers): Synthetic agents that exclusively block the catalytic center of the enzyme. Examples: argatroban, dabigatran etexilate.